Cancer Diagnosis in Patient Given LentiGlobin Revised to Severe Anemia

A patient diagnosed initially with the blood cancer myelodysplastic syndrome (MDS) after receiving LentiGlobin, Bluebird Bio’s investigational gene therapy for sickle cell disease (SCD), now has a revised diagnosis of transfusion-dependent anemia, the company announced.